The metabolic outcomes of growth hormone treatment in children are gender specific

Alessandro Ciresi, Stefano Radellini, Valentina Guarnotta, Maria Grazia Mineo and Carla Giordano

Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), University of Palermo, Palermo, Italy

Correspondence should be addressed to C Giordano: carla.giordano@unipa.it

Abstract

Objective: To evaluate the impact of gender on the clinical and metabolic parameters in prepubertal growth hormone deficiency (GHD) children at diagnosis and during GH treatment (GHT).

Design: The data of 105 prepubertal children (61 males, 44 females, mean age 6.8 ± 0.7 years) affected by idiopathic GHD were retrospectively evaluated.

Methods: Body height, BMI, waist circumference (WC), IGF-I, HbA1c, lipid profile, fasting and after-OGTT glucose and insulin levels, insulin sensitivity and secretion indices were evaluated at baseline and after 24 months of GHT.

Results: At baseline, no significant difference was found in all clinical, hormonal and metabolic parameters between males and females. After 24 months of GHT, both males and females showed a significant increase in height (both $P < 0.001$), BMI (both $P < 0.001$), WC ($P < 0.001$ and $P = 0.004$, respectively), IGF-I (both $P < 0.001$), fasting glucose ($P < 0.001$ and $P = 0.001$, respectively), fasting insulin (both $P < 0.001$) and Homa-IR (both $P < 0.001$), with a concomitant significant decrease in insulin sensitivity index (ISI) (both $P < 0.001$) and oral disposition index (Dlo) ($P = 0.001$ and $P < 0.001$, respectively). At 24 months of GHT, females showed significantly higher BMI ($P = 0.027$), lower ISI ($P < 0.001$) and Dlo ($P < 0.001$), in concomitance with a significant greater change from baseline to 24 months of BMI ($P = 0.013$), WC ($P < 0.001$), ISI ($P = 0.002$) and Dlo ($P = 0.072$), although the latter does not reach statistical significance.

Conclusions: Twenty-four months of GHT in prepubertal children leads to different metabolic outcomes according to gender, with a greater reduction in insulin sensitivity in females, regardless of auxological and hormonal parameters. Therefore, prepubertal GHD females should probably need a more proper monitoring in clinical practice.

Introduction

The sexual dimorphism in the mechanisms involved in the regulation of somatotroph axis is well documented, and it might account for some of the sex differences in growth rate and body composition (1). Indeed, sex hormones are one of the most influential regulators of growth hormone (GH) secretion and action, with different mechanisms (2). Androgens and estrogens exert opposite endocrine-mediated effects on insulin-like growth factor (IGF)-I production and metabolic parameters. Androgens affect circulating IGF-I indirectly via increased GH secretion, thus enhancing the peripheral GH action. In addition, testosterone modulates peripheral action of GH on the growth plate and liver by enhancing GH receptor expression (3). Conversely, estrogens reduce hepatic IGF-I production, consequently enhancing GH secretion and inhibit the function of the GH receptor (4). In addition, somatostatin also plays a role in the sexual dimorphism of GH secretion (5).
Indeed, high levels of estrogen receptors are expressed in the pituitary, regulating GH gene expression and reducing somatostatin receptor expression, leading to enhanced GH secretion (6). Lastly, the role of gender and sex steroids in modulating the clearance of GH must be taken into account (7). Therefore, women have higher GH secretion rates, due to both higher amplitude and higher frequency of the secretory pattern, and both baseline and post-glucose GH nadir concentrations are greater in women than in men (8, 9).

In healthy subjects, GH and IGF-I levels decline significantly with age in both sexes, while men show lower baseline and mean GH levels than women mainly due to the action of estradiol on the neuroendocrine regulation of pulsatile GH release (10).

This complex interplay between sex hormones and the GH/IGF-I axis has a clinically relevant impact in patients with hypopituitarism and the gender-dimorphic GH secretion pattern must be taken into account both in diagnosis of GH deficiency (GHD) and in detection of the appropriate and effective dose of GH replacement treatment (GHT) to be used (11).

Indeed, in hypopituitary patients, GHT produces a greater increase in plasma IGF-I in men, and women require a higher GH dose due to lower responsiveness to standard GH doses (12, 13).

The sexual dimorphism of GH secretion also results in a different expression of some genes involved in glucose and lipid metabolism. There is strong evidence that estrogens can influence the GH-regulated endocrine and metabolic functions in the human liver, and testosterone maximizes the metabolic benefits of GH (2, 14).

Height and weight gain or body composition become sexually dimorphic around the time of puberty, when males more rapidly gain muscle and bone and lose fat than females (1) and the close relationship between GH and gonadal steroid levels during puberty suggests that gonadal steroids may also stimulate linear growth by enhancing pituitary GH secretion (15).

Conversely, the relationship between GH and gonadal steroid levels in children is difficult to establish because steroid levels are very low prior to puberty. Therefore, although the clinical features related to sexual dimorphism of the somatotroph axis have been well demonstrated in GHD adults, to date, very few studies about gender difference are available in prepubertal GHD children.

The aim of this study was to evaluate the impact of gender on the clinical and metabolic parameters in a large series of prepubertal GHD children at diagnosis and during GHT.

Subjects and methods

We retrospectively evaluated the data of 105 children (61 males, 44 females, mean age 6.8 ± 0.7 years; range 4.3–9.4) affected by idiopathic GHD who were consecutively admitted to the Section of Endocrinology of the University of Palermo from January 2013 to December 2017 and underwent GHT for at least 24 consecutive months. Fifty-one healthy subjects, matched for sex (33 males, 18 females), age (mean age 6.7 ± 0.6 years; range 4–7.8), stature and pubertal status, were recruited as a control group at baseline among children referred for short stature. In this group, screening for short stature did not reveal endocrine disease and GHD was excluded. We excluded children affected by organic GHD or multiple pituitary hormone deficiency or receiving other hormonal replacement treatment to avoid interference with the metabolic parameters evaluated. All children, including the older ones, were in the first stage of sexual development according to the criteria of Marshall and Tanner (girls with Tanner breast stage B1; boys with testicular volume <4 mL) to avoid any interference of puberty with the auxological and metabolic parameters analyzed, and they maintained their prepubertal clinical and hormonal status for the entire follow-up (i.e. FSH and LH <1 U/mL, total testosterone and 17β-estradiol <0.50 ng/mL and <5 pg/mL in males and females, respectively). Similarly, no signs of clinical or biochemical adrenarche were detected during the entire follow-up (i.e. dehydroepiandrosterone sulphate <0.48 μmol/L or 18μg/dl in all children). GHD was diagnosed according to the criteria of the GH Research Society (16).

Specifically, as auxological criteria, we considered height more than 2 standard deviations (s.d.) below the mean and growth velocity more than 1 s.d. below the mean for age, or, without severe short stature, a growth velocity more than 2 s.d. below the mean over 1 year. As radiological criteria, we considered a bone age delay, estimated from an X-ray of the left wrist and hand and evaluated according to the methods of Greulich and Pyle, of at least 1 year with respect to the chronological age (17).

Biochemically, GHD was diagnosed by failure of GH to respond to the glucagon stimulation test (GST) and the insulin tolerance test (ITT), with GH peaks below 8 μg/L.
according to the Italian criteria of appropriateness of use and reimbursement of GHT in children (18).

Neuroimaging, with magnetic resonance of the hypothalamic–pituitary region, was performed in all GHD children with more severe GHD (GH peak ≤3 µg/L) and did not show significant pituitary abnormalities.

All GHD children received GH once daily at bedtime with a pen injection system. IGF-I levels and growth velocity allowed us to determine the GH dose. On average, in all patients, the initial daily dose of GH was 0.025 mg/kg, and it was gradually increased to 0.027–0.028 mg/kg from month 6 to 12, to 0.029–0.030 mg/kg from month 12 to 18 and to 0.030–0.032 mg/kg from month 18 to 24 in order to achieve the above-mentioned targets.

Study protocol

In all children at baseline, we measured body height (expressed as s.d.), BMI s.d. and waist circumference (WC). GH secretion was evaluated by GH levels during GST and ITT, performed on two different days. During GST, blood samples were collected at 0, 30, 60, 90, 120, 150, 180 and 240 min after the injection of 30 µg/kg (up to 1000 µg) intramuscularly of glucagon (GlucaGen, NovoNordisk), for measurements of GH. Blood samples for GH were also measured during ITT (0.1 U/kg of body weight of human Humulin R insulin) at baseline and at 30, 60, 90 and 120 min after insulin administration and results were accepted with blood glucose lower than 2.2 mmol/L (40 mg/dL).

On a different day, a blood sample was drawn after an overnight fast for the measurement of hemoglobin A1c (HbA1c), IGF-I concentrations and lipid profile, including total and high-density lipoprotein (HDL) cholesterol and triglycerides. Low-density lipoprotein (LDL) cholesterol levels were evaluated by the following formula: total cholesterol–(HDL cholesterol–triglycerides/5). This sample also served as the baseline sample for an oral glucose tolerance test (OGTT). Blood samples were collected every 30 min for 2 h for glucose and insulin measurements.

As surrogate estimates of insulin sensitivity we considered the homeostasis model assessment estimate of insulin resistance (Homa-IR) (19) and the insulin sensitivity index (ISI), a composite index derived from the OGTT and validated by Matsuda and DeFronzo (20). The oral disposition index (D Io) was used to evaluate the ability of the β-cell to regulate its insulin response to stimuli based on differences in insulin sensitivity.

The D Io was calculated at the time 0′ and 30′ during OGTT as described (21), using the following formula, where insulin levels are expressed in IU/mL and glucose levels in mmol/L: D Io=( Δ insulin 0′-30′/Δ glucose 0′-30′)×1/fasting insulin.

After the diagnosis of GHD was made, in GHD children in addition to auxological parameters and IGF-I measurement we performed OGTT (for glucose and insulin) after 12 and 24 months of GHT. In the control group, these evaluations were only performed at baseline.

For the analyses, we also considered the change (delta) in clinical and metabolic parameters from baseline to 24 months of GHT. The Institutional Ethics Committee of the University of Palermo approved this study. At the time of hospitalization, an informed consent for the scientific use of the data was obtained from both the participants and their parents.

Hormone and biochemical assays

Glucose was measured in the centralized accredited laboratories of the University of Palermo with the standard methods. HbA1c levels were determined by HPLC with an ion-exchange resin (BioRad D10, BioRad). Serum insulin was measured by electrochemiluminescence (ECLIA, Elecsys Insulin, Roche). The sensitivity of the method was 0.4 µU/mL. The normal range (µU/mL) was 2.6–24.9. Serum GH levels were measured by Immunoassay in electrochemiluminescence (ECLIA, Elecsys hGH, Roche). The lower limit of detection of the assay was 0.030 µg/L. The intra- and inter-assay coefficients of variation (CV) were 0.6–5.0 and 3.8–5.0%, respectively. We reported GH concentrations in µg/L of IS 98/574. Serum IGF-I levels were measured by means of a chemiluminescent immunometric assay (Immulite 2000; Diagnostic Products Corp., Los Angeles, CA, USA) using murine monoclonal anti-IGF-I antibodies. The standards were calibrated against the World Health Organization second IS 87/518. The sensitivity was 1.9 µg/L. The intra- and inter-assay CVs were 2.3–3.9% and 3.7–8.1%, respectively.

Statistical analysis

The Statistical Packages for Social Sciences SPSS, version 19 was used for data analysis. Baseline characteristics were presented as mean±s.d. for continuous variables (normality of distribution for the quantitative variables was assessed with the Kolmogorov–Smirnov test); rates and proportions were calculated for categorical data. The differences between groups were evaluated with
the t-test. A P value <0.05 was considered statistically significant.

Results

Children with GHD vs controls

The clinical, hormonal and metabolic parameters of control subjects and GHD children in full at diagnosis and after 24 months of GHT are shown in Table 1.

At baseline, GHD children showed significantly lower height (P<0.001), IGF-I (P<0.001) and GH peak after GST (P<0.001) and ITT (P<0.001) than control subjects. No significant difference in BMI and WC between GHD children and controls was found. Similarly, no difference was found in all metabolic parameters analyzed (Table 1).

After 24 months of GHT, GHD children showed a significant increase in height (P<0.001), BMI (P<0.001), WC (P<0.001) and IGF-I (P<0.001).

Regarding the metabolic parameters, GHD children showed a significant increase in fasting glucose (P<0.001), fasting insulin (P<0.001) and Homa-IR (P<0.001), with a concomitant significant decrease in ISI (P<0.001) and DIo (P<0.001). No significant change was found in Hba1c levels and lipid profile (Table 1).

Table 1 Clinical, hormonal and metabolic parameters of control subjects and GHD children in full at diagnosis and after 24 months of GH treatment.

| Gender | Controls No 51 Subjects (%) | GHD (baseline) No 105 Subjects (%) | GHD (24 months) No 105 | P | P* |
|--------|------------------------------|-----------------------------------|-------------------------|---|---|
|        |                              |                                    |                         |   |    |
|        | Gender                       |                                   |                          |   |    |
|        | Males                        | 33 (65)                           | 61 (58)                 | 0.130 | – |
|        | Females                      | 18 (35)                           | 44 (42)                 |     |    |
|        | Age (years)                  | 6.7 ± 0.6                         | 6.8 ± 0.7               | – | 0.424 |
|        | Height (s.d.)                | –1.9 ± 0.3                        | –2.3 ± 0.4              | –1.4 ± 0.4 | <0.001 |
|        | BMI (s.d.)                   | –0.5 ± 0.2                        | –0.7 ± 0.5              | –0.4 ± 0.4 | 0.130 |
|        | Waist circumference (cm)     | 59 ± 7                            | 62 ± 10                 | 65 ± 9 | 0.101 |
|        | GH peak during GST (µg/L)    | 11.2 ± 6.1                        | 3.5 ± 2.3               | – | <0.001 |
|        | GH peak during ITT (µg/L)    | 14.9 ± 7.6                        | 4.5 ± 2.5               | – | <0.001 |
|        | IGF-I (s.d.)                 | 0.3 ± 0.4                         | –0.3 ± 0.5              | 0.4 ± 0.5 | <0.001 |
|        | Fasting glucose (mmol/L)     | 4.1 ± 0.3                         | 4.1 ± 0.6               | 4.5 ± 0.4 | 0.871 |
|        | Fasting insulin (µU/mL)      | 3.7 ± 3.1                         | 3.8 ± 3.3               | 8.6 ± 4.6 | 0.906 |
|        | HbA1c (%)                    | 5.2 ± 0.2                         | 5.1 ± 0.2               | 5.1 ± 0.2 | 0.372 |
|        | Homa-IR                      | 0.7 ± 0.6                         | 0.7 ± 0.7               | 1.7 ± 1 | 0.679 |
|        | ISI                          | 10.1 ± 3.3                        | 11.1 ± 4.4              | 6.9 ± 4.2 | 0.125 |
|        | Dlo                          | 6 ± 3.6                           | 5 ± 3.5                 | 2.9 ± 2 | 0.111 |
|        | Total cholesterol (mmol/L)   | 4.1 ± 0.6                         | 4.1 ± 0.7               | 4.1 ± 0.6 | 0.981 |
|        | HDL cholesterol (mmol/L)     | 1.7 ± 0.4                         | 1.6 ± 0.3               | 1.6 ± 0.3 | 0.149 |
|        | LDL cholesterol (mmol/L)     | 2 ± 0.6                           | 2.2 ± 0.6               | 2.1 ± 0.5 | 0.285 |
|        | Triglycerides (mmol/L)       | 1.6 ± 0.7                         | 1.5 ± 0.5               | 1.6 ± 0.5 | 0.284 |

P = difference between controls and GHD children at baseline; P* = difference between GHD children at baseline and after 24 months of GH treatment.

BMI, body mass index; Dlo, oral disposition index; GST, glucagon stimulation test; Homa-IR, homeostasis model assessment estimate of insulin resistance; ISI, insulin sensitivity index; ITT, insulin tolerance test; s.d., standard deviation; WC, waist circumference.
Table 2  Gender-specific clinical, hormonal and metabolic parameters of GHD children at diagnosis and after 24 months of GH treatment.

|                      | Males             | Females            |
|----------------------|-------------------|--------------------|
|                      | Baseline Mean ± s.d. | 24 months Mean ± s.d. | P      | Baseline Mean ± s.d. | 24 months Mean ± s.d. | P' | P** | P*** |
| Age (years)          | 6.7 ± 0.5         | –                  | –      | 6.9 ± 0.9         | –                  | – | 0.233   |
| Height (s.d.)        | –2.2 ± 0.3        | –1.4 ± 0.3         | <0.001 | –2.3 ± 0.4        | –1.4 ± 0.4         | <0.001 | 0.168 | 0.608 |
| BMI (s.d.)           | –0.8 ± 0.5        | –0.6 ± 0.4         | <0.001 | –0.6 ± 0.4        | –0.2 ± 0.3         | <0.001 | 0.246 | 0.027 |
| WC (cm)              | 62 ± 10           | 64 ± 8.5           | 0.004  | 62 ± 10           | 67 ± 9.4           | <0.001 | 0.967 | 0.059 |
| GST-GH peak (µg/L)   | 3.8 ± 2.2         | –                  | –      | 2.9 ± 2.4         | –                  | – | 0.067 | – |
| ITT-GH peak (µg/L)   | 4.2 ± 2.6         | –                  | –      | 4.9 ± 2.3         | –                  | – | 0.170 | – |
| IGF-I (s.d.)         | –0.3 ± 0.4        | 0.4 ± 0.4          | <0.001 | –0.3 ± 0.5        | 0.4 ± 0.5          | <0.001 | 0.495 | 0.623 |
| Fasting glucose (mmol/L) | 4.2 ± 0.4      | 4.5 ± 0.4          | <0.001 | 4.0 ± 0.7        | 4.5 ± 0.4          | 0.001 | 0.093 | 0.587 |
| Fasting insulin (µU/mL) | 3.3 ± 3.1     | 8.4 ± 4.4          | <0.001 | 4.3 ± 3.5        | 9.2 ± 4.9          | <0.001 | 0.137 | 0.514 |
| HbA1c (%)            | 5.2 ± 0.2         | 5.2 ± 0.2          | 0.744  | 5.1 ± 0.2        | 5.1 ± 0.3          | 0.739 | 0.158 | 0.295 |
| Homa-IR              | 0.6 ± 0.6         | 1.7 ± 1.1          | <0.001 | 0.8 ± 0.7        | 1.8 ± 1.1          | <0.001 | 0.178 | 0.657 |
| ISI                  | 11.5 ± 3.8        | 8.4 ± 4.3          | <0.001 | 10.6 ± 4.2       | 5.9 ± 4.2          | <0.001 | 0.286 | <0.001 |
| D10                  | 5.3 ± 3.8         | 3.5 ± 2.1          | 0.001  | 4.7 ± 3          | 2.1 ± 1.5          | <0.001 | 0.424 | <0.001 |
| Total cholesterol (mmol/L) | 4.1 ± 0.8      | 4.1 ± 0.7          | 0.137  | 4.1 ± 0.6        | 4.2 ± 0.6          | 0.248 | 0.838 | 0.458 |
| HDL cholesterol (mmol/L) | 1.6 ± 0.3      | 1.6 ± 0.3          | 0.781  | 1.5 ± 0.3        | 1.6 ± 0.4          | 0.260 | 0.105 | 0.754 |
| LDL cholesterol (mmol/L) | 2.1 ± 0.7      | 2.1 ± 0.4          | 0.179  | 2.2 ± 0.5        | 2.1 ± 0.6          | 0.585 | 0.672 | 0.566 |
| Triglycerides (mmol/L) | 1.4 ± 0.5      | 1.6 ± 0.4          | 0.217  | 1.5 ± 0.4        | 1.6 ± 0.5          | 0.307 | 0.218 | 0.647 |

P = difference from baseline to 24 months of GH treatment in males; P' = difference from baseline to 24 months of GH treatment in females; P** = difference between males and females at baseline; P*** = difference between males and females at 24 months of GH treatment.

The sexual dimorphism of the somatroph axis has been well documented in healthy subjects and in adult patients affected by both GH excess and deficiency (12, 22, 23, 24). GHD adolescents also showed a gender difference in the clinical effect of treatment, since in the transition phase, GHT determined a greater gain in lean body mass and reduction in fat mass in males than in females (25), although not all studies are concordant. In fact, Mauras et al. showed similar sensitivity to GHT for body composition changes, lipolysis, lipid and glucose concentrations in males and females during puberty and just a higher IGF-I response in males, which does not translate into differences in linear growth (26). The effect of gender on clinical response to GHT in children has been poorly explored. Although in the present study all children were prepubertal during the entire follow-up, as demonstrated by both clinical and hormonal parameters, previous studies demonstrated that sex steroid levels in children, although much lower, may display sexual dimorphism. Indeed, prepubertal girls show higher estrogen levels than prepubertal boys, and moreover, boys have higher testosterone levels compared to prepubertal girls (27). Therefore, very low levels of sex steroids can probably also modulate the GH axis or clinical response to GHT.

Rose et al. in a retrospective study evaluated whether this was a sex steroid effect during the first 2 years of...
GHT in 147 prepubertal children, finding no evidence of gender difference in growth response (28).

Similarly, no significant gender differences in metabolic parameters were observed both at baseline and during GHT by Salerno et al. (29). Conversely, Cohen et al. in a randomized prospective dose-ranging study demonstrated a clear gender impact on both auxological and biochemical parameters in a larger cohort of GHD children during GHT, concluding that there is a gender difference in GH sensitivity. Indeed, the authors showed that males had a linear GH dose response, whereas females had an apparent plateau of both growth and IGF-I levels, and these data were also confirmed when only prepubertal children were analyzed, indicating that the gender difference observed is not related to the occurrence of puberty (30). Savendahl et al. also reported a significant gender difference in 2-year growth response to GHT in a large cohort of prepubertal GHD children, although no difference was observed in the change in IGF-I levels (31).

In our study, both GHD children taken together and grouped according to gender showed a significant and similar auxological improvement and normalization of IGF-I levels during GHT. However, if apparently all children had increased BMI and WC, the direct comparison between males and females after 24 months of GHT showed a greater increase in fat mass in females, as confirmed by the calculated delta of BMI and WC. These data are in agreement with a previous study by Kuromaru et al. who demonstrated similar auxological benefits but partial gender-specific metabolic effects of GHT in 62 children. Indeed, the authors showed a significant change in percent body fat both in boys and girls during the first 6 months of treatment, although body fat remained constant in boys but started to increase in girls from the 18th month of treatment (32).

Few studies have evaluated the gender differences of metabolic features in children with GHD. GHT is known to impact on glucose metabolism, by increasing insulin secretion and decreasing insulin sensitivity, with a discordant impact on glucose levels (33, 34). In the present study, GHD children at baseline did not show any significant metabolic difference from controls, in agreement with previous studies (35, 36, 37).

After 24 months of GHT, regardless of gender, all GHD children showed a significant increase in fasting glucose and insulin levels with a concomitant impairment in insulin sensitivity and β-cell function. Indeed, although fasting glucose and HbA1c levels were always maintained within the normal range, a significant decrease in insulin sensitivity, demonstrated by an increase in Homa-IR and a decrease in ISI, was found in all children after GHT. These data are quite consistent with the majority of existing studies (38, 39, 40, 41, 42, 43). In addition, a significant decrease in the DIo was found in all children, in agreement with a previous study (44). The DIo, which expresses the capacity of β-cells to compensate adequately for insulin resistance through increased insulin secretion, has been shown to be a predictor of development of diabetes (21). Therefore, its reduction is considered an index of inadequate β-cell capacity to counteract the reduction in insulin sensitivity and a risk factor for future development of overt diabetes (45). However, when we considered the change in metabolic parameters according to gender, females showed a greater deterioration in insulin

**Figure 1**
Change (delta) in BMI, waist circumference (WC), insulin sensitivity index (ISI) and oral disposition index (DIo) from baseline to 24 months of GH treatment in GHD children grouped according to gender.
sensitivity, as demonstrated by the higher reduction in ISI, with a concomitant greater reduction in DIo, while no gender difference was found in IGF-I levels.

Therefore, the gender difference in the metabolic outcomes of GHT observed in our patients were unlikely due to being mediated by the IGF-I levels, which were always within the normal range during the observational period and similar in males and females. However, to minimize the impact of the different age of patients on IGF-I, we considered the delta in IGF-I during GHT, rather than absolute IGF-I levels, and it too proved comparable in the two groups of children. Similarly, a different GH dose in males and females can be excluded as the cause of the different metabolic outcomes in this study, since the dose was similar in both groups of patients during the entire follow-up. This finding suggests that there are other factors than IGF-I change or different GH dose that may mediate the gender difference in metabolic outcomes during GHT.

Notably, in our study, females showed a greater increase in BMI and WC than males, as demonstrated by the comparison of these parameters at 24 months and as confirmed by the significant difference in delta of BMI and WC between the two groups. Therefore, the greater change in BMI and WC found in females suggests that adiposity might be a mediator of the different metabolic effects of GHT.

Indeed, a different gender response to GHT secondary to body composition changes has been widely demonstrated in GHD adults (46, 47), although not all studies are concordant with a gender-related difference in the long-term metabolic effects of GHT (48). Conversely, the potential impact of adrenal androgen synthesis, which has also been demonstrated to be linked to GH/IGF-I axis and metabolic parameters in prepuberty (27), may be ruled out in our study.

This study has undoubtedly some limitations represented by the relative small size of the population and by the lack of data for the control group during the 24 months of follow-up. Indeed, the insulin sensitivity seems to decrease with age, probably due to the physiological effect of steroids production or the modifications of body composition during the peripubertal period, also in normal children (49, 50). For these reasons, it is not possible to determine with absolute certainty whether the greater increase in BMI and WC and decrease in ISI shown in females are exclusively related to GHT or would have occurred anyway, although in our study, all children remained clinically and biochemically prepubertal during the entire follow-up. More reliable data on body composition evaluated by dual energy X-ray absorptiometry (DEXA) will certainly confirm these important data in future studies. In addition, a close link between the decrease of DIo and the risk for diabetes in this population of GHD children can only demonstrated through longitudinal studies, and it would be interesting to know what happens to DIo after GHT will be discontinued. Conversely, the strength of this study lies in the fact that it evaluated the gender difference in metabolic outcomes of GHT in children as its primary and main objective.

In conclusion, this study highlights that 24 months of GHT in children leads to different metabolic outcomes according to gender, regardless of auxological and hormonal parameters. Therefore, the follow-up of prepubertal GHD children during GHT should probably also be modulated and optimized not only according to auxological and biochemical response, but also considering the patient’s gender. Specifically, prepubertal GHD females should probably need a more proper monitoring in clinical practice aimed at correct lifestyle during GHT to prevent metabolic alterations, although studies with longer follow-up and a larger cohort of patients are required to confirm these preliminary results and to establish with greater certainty whether GHD females need more surveillance during GHT or, alternatively, different GHT doses.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References
1 Gatford KL, Egan AR, Clarke IF & Owens PC. Sexual dimorphism of the somatotrophic axis. Journal of Endocrinology 1998 157 373–389. (https://doi.org/10.1677/joe.0.1570373)
2 Bizzniece V & Ho KKY. Sex steroids and the GH axis: implications for the management of hypopituitarism. Best Practice and Research: Clinical Endocrinology and Metabolism 2017 31 59–69. (https://doi.org/10.1016/j.cenm.2017.03.003)
3 Yu YM, Domene HM, Szent J, Counts DR & Cassorla F. Developmental changes and differential regulation by testosterone and estradiol of growth hormone receptor expression in the rabbit. European Journal of Endocrinology 1996 135 S83–S90. (https://doi.org/10.1530/eje.0.1350583)
4 Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ & Ho KK. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated
Gender differences in GHD children

Ciresi A, Cicciò F, Amato MC & Giordano C. Revaluation of the Italian Medicines Agency (AIFA).

1. van den Berg G, Veldhuis JD, Frölich M & Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. Journal of Clinical Endocrinology and Metabolism 1996 81 2460–2467. (https://doi.org/10.1210/jcem.81.7.8675561)

2. Veldhuis JD, Patrie JT, Brill KT, Weltman AJ, Burman P, Johansson AG, Siegbahn A, Vessby B & Karlsson FA. Growth hormone action in puberty: implications for efficacy and safety. Journal of Clinical Endocrinology and Metabolism 2004 89 6291–6296. (https://doi.org/10.1210/jc.2004-0644)

3. Burman P, Johansson AG, Sieghahn A, Vesby B & Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. Journal of Clinical Endocrinology and Metabolism 1997 82 550–555.

4. Fernández-Pérez L, Guerra B, Díaz-Chico JC & Flores-Morales A. Estrogens regulate the hepatic effects of growth hormone, a hormonal interplay with multiple fates. Frontiers in Endocrinology 2013 4 66. (https://doi.org/10.3389/fendo.2013.00066)

5. Hull KL & Harvey S. GH as a co-gonadotropin: the relevance of correlative changes in GH secretion and reproductive state. Journal of Endocrinology 2002 172 1–19. (https://doi.org/10.1677/joe.0.1720001)

6. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. Journal of Clinical Endocrinology and Metabolism 2000 85 3990–3993. (https://doi.org/10.1210/jc.2000-8634)

7. Anderson M. Use of the Greulich-Pyle “Atlas of Skeletal Development of the Hand and Wrist” in a clinical context. American Journal of Physical Anthropology 1971 35 347–352. (https://doi.org/10.1002/ajpa.1330350309)

8. Ciresi A, Cicciò F, Amato MC & Giordano C. Revaluation of the Italian Medicines Agency (AIFA). Journal of Endocrinological Investigation 2015 38 1301–1307. (https://doi.org/10.1007/s40618-015-0314-7)

9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412–419. (https://doi.org/10.1007/BF00280883)

10. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462–1470. (https://doi.org/10.2337/diacare.22.9.1462)

11. Utschneider KM, Prigoen RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY & Kahn SE. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009 32 335–341. (https://doi.org/10.2337/dc08-1478)

12. Colao A, Amato G, Pedroncelli AM, Baldelli R, Grotti S, Gasco V, Petretta M, Carella C, Pagani G, Tambura G, et al. Gender- and age-related differences in the endocrine parameters of acromegaly. Journal of Endocrinological Investigation 2002 25 532–538. (https://doi.org/10.1007/BF03345496)

13. Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Colaco D, Colacchi F, Galvanino MA & Huygens J. The metabolic profile in active acromegaly is gender-specific. Journal of Clinical Endocrinology and Metabolism 2013 98 E51–E59. (https://doi.org/10.1210/jc.2012-2896)

14. Parkinson C, Ryder WD, Traber PJ & Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. Journal of Clinical Endocrinology and Metabolism 2001 86 5240–5244. (https://doi.org/10.1210/jcem.86.11.8006)

15. Attanasio AJ, Shavrikova E, Blum WE, Cromer M, Child CJ, Paskova M, Lebl J, Chipman JF, Shalet SM & Hypopituitary Developmental Outcome Study Group. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 2004 89 4857–4862. (https://doi.org/10.1210/jcem.89.8.4857)

16. Muraus N, Bishop K & Welch S. Growth hormone action in puberty: effects by gender. Growth Hormone and IGF Research 2007 17 463–471. (https://doi.org/10.1016/j.ygih.2007.04.011)

17. Querci G, Rivarola MA, Chaler E, Maceiras M & Belgorosky A. Relationship between the growth hormone/insulin-like growth factor-1 axis, insulin sensitivity, and adrenal androgens in normal prepubertal and pubertal girls. Journal of Clinical Endocrinology and Metabolism 2003 88 1389–1393. (https://doi.org/10.1210/jc.2002-020979)

18. Rose SR, Shulman DI, Larsson P, Walsk R, Wills S & Bakker B. Gender does not influence prepubertal growth velocity during standard growth hormone therapy – analysis of United States KIGS data. Journal of Pediatric Endocrinology and Metabolism 2005 18 1045–1051.

19. Salerno M, Esposito V, Farina V, Radetti G, Umbaldo A, Capalbo D, Spinelli L, Muzza S, Lombardi G & Colao A. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. Journal of Clinical Endocrinology and Metabolism 2006 91 1288–1295. (https://doi.org/10.1210/jc.2005-0981)

20. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG & American Nondiabetic Clinical Trials Group. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. Journal of Clinical Endocrinology and Metabolism 2002 87 90–98. (https://doi.org/10.1210/jcem.87.1.8150)

21. Sávendahl L, Blankenstein O, Oliver J, Christesen HT, Lee P, Pedersen BT, Bakov V & Ross J. Gender influences short-term growth
hormone treatment response in children. *Hormone Research in Paediatrics* 2012 **77** 188–194. (https://doi.org/10.1159/000337570)

32. Kuromaru R, Kohno H, Ueyama N, Hassan HM, Honda S & Har a T. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabolic effects. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 3890–3896. (https://doi.org/10.1210/jcem.83.11.5261)

33. Heptulla RA, Boulware SD, Caprio S, Silver D, Sherwin RS & Tamborlane WV. Decreased insulin sensitivity and compensatory hyperinsulinemia after hormone treatment in children with short stature. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 3234–3238. (https://doi.org/10.1210/jcem.82.10.4302)

34. Saenger P. Metabolic consequences of growth hormone treatment in paediatric practice. *Hormone Research* 2000 **53** 60–69. (https://doi.org/10.1159/000053207)

35. Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, Galluzzo A, D’Acquisto G & Giordano C. Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. *European Journal of Endocrinology* 2007 **156** 353–360. (https://doi.org/10.1530/eje.1.02343)

36. Meazza C, Elsedly HH, Pagani S, Bozzola E, El Kholy M & Bozzola M. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. *Hormone and Metabolic Research* 2014 **46** 219–223. (https://doi.org/10.1055/s-0033-1358730)

37. Capalbo D, Esposito A, Improda N, Wasienska MG, Di Mase R, De Luca F, Bruzzese D & Salerno M. Glucose homeostasis in GHD children during long-term replacement therapy: a case-control study. *Endocrine* 2018 **59** 643–650. (https://doi.org/10.1007/s12020-017-1408-0)

38. Ciresi A & Giordano C. One-hour post-load plasma glucose level is associated with a worse metabolic profile in children with GH deficiency. *Journal of Endocrinological Investigation* 2018 **41** 789–797. (https://doi.org/10.1007/s40618-017-0805-9)

39. Ciresi A, Pizzolant i G, Leotta M, Guarinotta V, Teresi G & Giordano C. Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children. *Journal of Endocrinological Investigation* 2016 **39** 1023–1030. (https://doi.org/10.1007/s40618-016-0475-z)

40. Ciresi A, Guarinotta V, Pizzolant i G & Giordano C. Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency. *Growth Hormone and IGF Research* 2018 **39** 40–44. (https://doi.org/10.1016/j.ghir.2017.12.007)

41. Cafiete R, Valle M, Martos R, Sánchez-Carrion A, Cafiete MD & van Donkelaar EL. Short-term effects of GH treatment on coagulation, fibrinolysis, inflammation, biomarkers and insulin resistance status in prepubertal children with GH deficiency. *European Journal of Endocrinology* 2012 **167** 255–260. (https://doi.org/10.1530/EJE-12-0214)

42. Salerno M, Esposito V, Farina V, Radetti G, Umbaldo A, Capalbo D, Spinelli L, Muzzica S, Lombardi G & Colao A. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. *Journal of Clinical Endocrinology and Metabolism* 2006 **91** 1288–1295. (https://doi.org/10.1210/jc.2005-0981)

43. Radetti G, Pasquino B, Gottardi E, Contadini IB, Rigon F & Aimaretti G. Insulin sensitivity in growth hormone-deficient children: influence of replacement treatment. *Clinical Endocrinology* 2004 **61** 473–477. (https://doi.org/10.1111/j.1365-2265.2004.02113.x)

44. Ciresi A, Amato MC & Giordano C. Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. *Journal of Endocrinological Investigation* 2013 **36** 351–359. (https://doi.org/10.1007/s40618-014-0184-4)

45. Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlgqvist G & Group L. Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes. *Diabetologia* 2004 **47** 782–793. (https://doi.org/10.1007/s00125-004-1393-8)

46. Span JP, Pieters GF, Sweep FG, Hermus AR & Smals AG. Gender differences in rLGH-induced changes in body composition in GH-deficient adults. *Journal of Clinical Endocrinology and Metabolism* 2001 **86** 4161–4165. (https://doi.org/10.1210/jcem.86.9.7815)

47. Abrahamsen B, Nielsen TL, Hangaard J, Gregersen G, Vahl N, Korsholm L, Hansen TB, Andersen M & Hagen C. Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency. *European Journal of Endocrinology* 2004 **150** 671–679. (https://doi.org/10.1530/eje.1.0150671)

48. Colao A, Di Somma C, Cuocolo A, Spinelli L, Aacmana W, Spiezia S, Rota F, Savarelli MC & Lombardi G. Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. *Journal of Clinical Endocrinology and Metabolism* 2005 **90** 5146–5155. (https://doi.org/10.1210/jc.2005-0597)

49. Caprio S, Plewe G, Diamond MP, Simonson DC, Boulware SD, Sherwin RS & Tamborlane WV. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. *Journal of Pediatrics* 1989 **114** 963–967. (https://doi.org/10.1016/S0022-3476(89)80438-X)

50. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW & Tamborlane WV. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. *Journal of Clinical Endocrinology and Metabolism* 1991 **72** 277–282. (https://doi.org/10.1210/jcem-72-2-277)

Accepted Preprint published online 20 June 2018

Received in final form 18 May 2018

Accepted 20 June 2018

This work is licensed under a Creative Commons Attribution 4.0 International License.